Ulipristal acetate: In uterine fibroids

Drugs

Volumn 72, Issue 8, 2012, Pages 1075-1085

  Croxtall, Jamie D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Ulipristal; Uterine leiomyoma

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ESTRADIOL; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LEUPRORELIN; LUTEINIZING HORMONE; MIFEPRISTONE; NEFAZODONE; PHENYTOIN; PROGESTERONE; RIFAMPICIN; RITONAVIR; ULIPRISTAL; VASCULOTROPIN;

ABDOMINAL PAIN; ACNE; ANEMIA; AREA UNDER THE CURVE; ARTICLE; DOWN REGULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; IN VITRO STUDY; INFLUENZA; INSOMNIA; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACODYNAMICS; PHARYNGITIS; PROTEIN EXPRESSION; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERUS MYOMA;

CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEIOMYOMA; NORPREGNADIENES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE HEMORRHAGE; UTERINE NEOPLASMS;

EID: 84861432519     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209400-000000000-00000     Document Type: Article

References (49)

1. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 2010; 28 (3): 180-203
2. Rein MS, Friedman AJ, Barbieri RL, et al. Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 1991 Jun; 77 (6): 923-6
3. Mashal RD, Fejzo ML, Friedman AJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 1994 Sep; 11 (1): 1-6 (Pubitemid 24273967)
4. Schwartz PE, Kelly MG. Malignant transformation of myomas: myth or reality? Obstet Gynecol Clin North Am 2006 Mar; 33 (1): 183-98, xii
5. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994 Mar; 83 (3): 414-8 (Pubitemid 24067812)
6. Ligon A, Morton C. Leiomyomata: heritability and cytogenetic studies. Hum Reprod Update 2001; 7 (1): 8-14 (Pubitemid 32111961)
7. Baird D, Duson D, Hill M, et al. High cumulative incidence of uterine leiomyoma in Black and White women: ultrasound evidence. Am J Ostet Gynecol 2003; 188 (1): 100-7 (Pubitemid 36135604)
8. Buttram Jr VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981 Oct; 36 (4): 433-45 (Pubitemid 11027013)
9. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. AmFam Physician 2007 May 15; 75 (10): 1503-8 (Pubitemid 46790333)
10. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002 Jun; 17 (6): 1424-30 (Pubitemid 34661784)
11. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008; 90 (5 Suppl.): S125-30
12. Parker WH. Uterine myomas: management. Fertil Steril 2007 Aug; 88 (2): 255-71 (Pubitemid 47212168)
13. Flynn M, Jamison M, Datta S, et al. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 2006 Oct; 195 (4): 955-64 (Pubitemid 44415640)
14. McCarthy-Keith DM, Armstrong AY. Innovations in uterine fibroid therapy. Therapy 2011; 8 (2): 189-200
15. Ravina J, Bouret J, Cirary-Vigneron N, et al. Application of particulate arterial embolization in the treatment of uterine fibromyomata. Bull Fr Nat Acad Med 1997; 18 (2): 1-10
16. Duhan N. Current and emerging treatments for uterine myoma: an update. Int J Womens Health 2011; 3 (1): 231-42
17. De Leo V, Morgante G, La Marca A, et al. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf 2002; 25 (11): 759-79 (Pubitemid 35178633)
18. Stewart EA. Uterine fibroids and evidence-based medicine: not an oxymoron. N Engl J Med 2012 Feb 2; 366 (5): 471-3
19. Flake G, Andersen J, Dixon D. Eitiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003; 111 (8): 1037-54 (Pubitemid 36826884)
20. Cohen O, Schindel B, Homburg R. Uterine leiomyomata: a feature of acromegaly. Hum Reprod 1998 Jul; 13 (7): 1945-6
21. Grattarola R, Li CH. Effect of growth hormone and its combination with estradiol-17b on the uterus of hypophysectomized-ovariectomized rats. Endocrinology 1959; 65 (5): 802-10
22. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995 Jan; 172 (1 Pt 1): 14-8
23. Maruo T. Progesterone and progesterone receptor modulator in uterine leiomyoma growth. Gynecol Endocrinol 2007; 23 (4): 186-7 (Pubitemid 46763730)
24. Hoekstra AV, Sefton EC, Berry E, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 2009 May; 94 (5): 1768-74
25. Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010 Jun; 151 (6): 2433-42
26. Yin P, Lin Z, Cheng YH, et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab 2007 Nov; 92 (11): 4459-66 (Pubitemid 350074770)
27. Yin P, Lin Z, Reierstad S, et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010 Feb 15; 70 (4): 1722-30
28. Chwalisz K, Perez MC, DeManno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26 (3): 423-38 (Pubitemid 40686652)
29. Pintiaux A, Chabbert-Buffet N, Foidart JM. Gynaecological uses of a new class of steroids: the selective progesterone receptor modulators. Gynecol Endocrinol 2009 Feb; 25 (2): 67-73
30. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009; 21 (4): 318-24
31. Maruo T, Ohara N, Matsuo H, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007; 75 (6 Suppl.): S99-103
32. Bouchard P, Chabbert-Buffet N, Fauser BCJM. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011; 96 (5): 1175-89
33. Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005; 11 (3): 293-307 (Pubitemid 40674206)
34. McKeage K, Croxtall JD. Ulipristal acetate: a review of its use in emergency contraception. Drugs 2011 May 7; 71 (7): 935-45
35. Electronic Medicines Compendium. Esmya 5mg tablets (ulipristal acetate) [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/26068/ SPC/Esmya+5+mg+ Tablets+(ulipristal+acetate)/[Accessed 2012 Mar 7]
36. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012 Feb 2; 366 (5): 409-20
37. Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012 Feb 2; 366 (5): 421-32
38. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007 Sep; 92 (9): 3582-9 (Pubitemid 47435338)
39. Ravet S, Munaut C, Blacher S, et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab 2008 Nov; 93 (11): 4525-31 (Pubitemid 352789556)
40. Attardi BJ, Burgenson J, Hild SA, et al. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002 Feb 25; 188 (1-2): 111-23 (Pubitemid 34242671)
41. Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005; 90 (2): 953-61 (Pubitemid 40279221)
42. Xu Q, Ohara N, Chen W, et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006; 21 (9): 2408-16 (Pubitemid 44530620)
43. Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14 (3): 181-91 (Pubitemid 351404891)
44. Brache V, Cochon L, Jesam C, et al. Immediate preovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010 Sep; 25 (9): 2256-63
45. Palanisamy GS, Cheon YP, Kim J, et al. A novel pathway involving progesterone receptor, endothelin-2, and endothelin receptor B controls ovulation in mice. Mol Endocrinol 2006 Nov; 20 (11): 2784-95 (Pubitemid 44833535)
46. Narvekar N, Critchley HO, Cheng L, et al. Mifepristoneinduced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod 2006 Sep; 21 (9): 2312-8 (Pubitemid 44530605)
47. McFarland F, Blithe HaD. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007; 13 (6): 567-80
48. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008 May; 21 (5): 591-8 (Pubitemid 351589653)
49. European Medicines Agency. Assessment report for Esmya [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Public-assessment-report/human/002041/WC500124088.pdf [Accessed 2012 Mar 30]